Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2025-12-07 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
自愿披露关于公司产品纳入国家医保目录的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the inclusion of a product into the National Medical Insurance Directory. It is a voluntary disclosure about product listing and related information, including risk warnings and regulatory references. There is no financial data, no report attached or referenced as being published, and no mention of shareholder meetings, voting, or management changes. The document is an official company announcement about a regulatory or product-related update, which does not fit into financial reports or meeting materials. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous company announcements that do not fit other specific categories.
2025-12-07 Chinese
关于召开职工代表大会暨选举职工代表董事的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Shenzhen Microcore Biotech Co., Ltd. regarding the convening of the employee representative meeting and the election of an employee representative director. It details the removal of certain employee representative supervisors and the election of a new employee representative director to the board. There is no financial data, no mention of financial results, no regulatory filings or audit reports, and no mention of shareholder votes or dividends. The content focuses on board/management changes specifically related to employee representative directors. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2025-12-05 Chinese
上海市通力律师事务所关于深圳微芯生物科技股份有限公司2025年第一次临时股东大会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter issued by a law firm regarding the legality of convening, attendance and voting procedures/results at Shenzhen Microchip Biotechnology’s 2025 first extraordinary shareholders meeting. It does not itself constitute the meeting notice or proxy solicitation materials, nor a pure voting‐results announcement published by the company. Rather, it is a compliance/legal opinion (attestation) addressed to the company. Such standalone legal opinions and compliance attestations fall under the general Regulatory Filings (RNS) category as per the Certification Rule and fallback guidelines.
2025-12-05 Chinese
2025年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2025 first extraordinary general meeting of shareholders of Shenzhen Microchip Biotechnology Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals, and legal witness statements. The content focuses on the official voting results and decisions made during the shareholders' meeting rather than the meeting materials or presentations. The document length is about 4,078 characters, which is sufficient to contain substantive voting results and details. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-12-05 Chinese
关于以集中竞价交易方式首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the company's first share repurchase through centralized bidding. It details the repurchase plan, including the amount, price range, purpose (employee stock ownership plan or equity incentive), and the actual repurchase executed on December 3, 2025. The document includes specific data on shares repurchased, prices, and compliance with relevant regulations. It is not a full financial report but a specific announcement about the company's share buyback activity. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and focused solely on the repurchase announcement, not a report or presentation.
2025-12-03 Chinese
关于向特定对象发行股票申请获得中国证券监督管理委员会同意注册批复的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the approval from the China Securities Regulatory Commission (CSRC) for a specific share issuance to designated investors. It includes details about the registration approval, the validity period, and the company's commitment to comply with regulations and disclose information timely. The document is short (808 characters) and serves as a formal announcement of the approval for a capital raising activity through share issuance. It does not contain financial statements or detailed financial data, nor is it a full report. Therefore, it fits the category of Capital/Financing Update (CAP).
2025-12-02 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.